# A Study of UX003 Recombinant Human Beta-Glucuronidase (rhGUS) Enzyme Replacement Therapy in Subjects With Mucopolysaccharidosis Type 7, Sly Syndrome (MPS 7)

> **NCT02432144** · PHASE3 · COMPLETED · sponsor: **Ultragenyx Pharmaceutical Inc** · enrollment: 12 (actual)

## Conditions studied

- Sly Syndrome
- MPS VII
- Mucopolysaccharidosis
- Mucopolysaccharidosis VII

## Interventions

- **DRUG:** UX003

## Key facts

- **NCT ID:** NCT02432144
- **Lead sponsor:** Ultragenyx Pharmaceutical Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-10
- **Primary completion:** 2019-01-14
- **Final completion:** 2019-01-14
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2020-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02432144

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02432144, "A Study of UX003 Recombinant Human Beta-Glucuronidase (rhGUS) Enzyme Replacement Therapy in Subjects With Mucopolysaccharidosis Type 7, Sly Syndrome (MPS 7)". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT02432144. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*